Li Bao

Li Bao

Auto-generated profile, based on publicly available information

Li Bao

Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RGRabia A. Gilani
Rabia A. Gilani
SPSameer Phadke
Sameer Phadke
LBLi Wei Bao
Li Wei Bao
ELEric J. Lachacz
Eric J. Lachacz
MDMichele L. Dziubinski
Michele L. Dziubinski
MSMatthew B. Soellner
Matthew B. Soellner
Purpose: c-Src has been shown to play a pivotal role in breast cancer progression, metastasis, and angiogenesis. In the clinic, however, the limited efficacy and high toxicity of existing c-Src inhibitors have tempered the enthusiasm for targeting c-Src. We developed a novel c-Src inhibitor (UM-164) that specifically binds the DFG-out inactive conformation of its target kinases. We hypothesized that binding the inactive kinase conformation would lead to improved pharmacologic outcomes by altering the noncatalytic functions of the targeted kinases. Experimental Design: We have analyzed the anti–triple-negative breast cancer (TNBC) activity of UM-164 in a comprehensive manner that includes in vitro cell proliferation, migration, and invasion assays (including a novel patient-derived xenograft cell line, VARI-068), along with in vivo TNBC xenografts. Results: We demonstrate that UM-164 binds the inactive kinase conformation of c-Src. Kinome-wide profiling of UM-164 identified that Src and p38 kinase families were potently inhibited by UM-164. We further demonstrate that dual c-Src/p38 inhibition is superior to mono-inhibition of c-Src or p38 alone. We demonstrate that UM-164 alters the cell localization of c-Src in TNBC cells. In xenograft models of TNBC, UM-164 resulted in a significant decrease of tumor growth compared with controls, with limited in vivo toxicity. Conclusions: In contrast with c-Src kinase inhibitors used in the clinic (1, 2), we demonstrate in vivo efficacy in xenograft models of TNBC. Our results suggest that the dual activity drug UM-164 is a promising lead compound for developing the first targeted therapeutic strategy against TNBC. Clin Cancer Res; 22(20); 5087–96. ©2016 AACR.

15 September 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
CLChao Liu
Chao Liu
YLYining Li
Yining Li
RSRen Sheng
Ren Sheng
XHXiaowan Han
Xiaowan Han
LBLi Bao
Li Bao
SSShuyi Si
Shuyi Si

2 July 2025 in World Neurosurgery
Verified
Journal Article
Open access
BZBoyu Zhang
Boyu Zhang
PJPu Jia
Pu Jia
GSGuan Shi
Guan Shi
MCMengmeng Chen
Mengmeng Chen
JZJunfeng Zhang
Junfeng Zhang
LBLi Bao
Li Bao
Degenerative lumbar spine pathologies are a major cause of chronic low back pain and radiculopathy. In recent years, unilateral biportal endoscopic (UBE) technology has been applied more in the treatment of lumbar disc herniation. However, there are few studies on UBE postoperative infection. We conducted a retrospective analysis of patient information from our medical center to summarize the diagnosis and treatment of surgical site infections following UBE. Data of patients who underwent UBE for lumbar disc herniation between October 2020 and October 2024 were reviewed, and basic patient information and potential risk factors for infection were statistically analyzed using Fisher exact test. Four hundred thirty-six patients were reviewed. Postoperative infections occurred in 3 patients. A statistically significant association was observed between diabetes mellitus and infection development (P < 0.05). All the patients had a good prognosis following treatment. Diabetes mellitus is a notable risk factor for postoperative infections after UBE. Early diagnosis, targeted antibiotic therapy, and timely surgical intervention using appropriate techniques are essential for achieving optimal treatment outcomes.

12 February 2023 in Geriatric Orthopaedic Surgery & Rehabilitation
Verified
Journal Article
Open access
GSGuan Shi
Guan Shi
LZLiang Zhang
Liang Zhang
HCHao Chen
Hao Chen
TSTianhao Su
Tianhao Su
PJPu Jia
Pu Jia
LBLi Bao
Li Bao
Introduction: This article introduced the management of a case with severe left lower extremity pain and forced hip flexion after posterior lumbar interbody fusion and a final diagnosis of left psoas hematoma. Materials and methods: Here we reported a case of a 65-year-old female received posterior lumbar interbody fusion (PLIF) for L4-L5 spondylolisthesis and L4 instability. On the postoperative day one, the hemoglobin level decreased from 108 g/L to 78 g/L. Meanwhile, the patient presented low back pain and inner thigh radiating pain (VAS pain scale = 8). The pain was so severe that it could be barely relieved by keeping left hip in flexion position. On the postoperative day 6, the pain was still severe even after taking mecobalamin, ankylosaurus, dehydrant agents and central pain relievers(VAS pain scale = 9). Computed Tomography indicated a left intramuscular hematoma image extending down to the left iliac fossa. Active hemorrhage of lumbar segmental arterial was detected by B-ultrasound. The patient then received vascular embolization under angiography on the postoperative day 7. Results: The pain in the low back and inner thigh were significantly relieved after the procedure (VAS3-4). On the postoperative day nineteen, the left hip can be fully extended, but the patient was still not able to stand on left leg without a walking stick. On the postoperative day 27, she was able to walk independently. Discussion: The main reason for the complication was the second conical dilation channel slipped and entered the lateral side of the vertebral body along the transverse process. After timely embolization, pain was significantly relieved and muscle strength was improved. Conclusions: Angiographic embolization is an effective treatment for psoas hematoma after posterior lumbar interbody fusion.

6 October 2023 in ESMO Open
Verified
Journal Article
Open access
NMN. Merrill
N. Merrill
NVN. Vandecan
N. Vandecan
AAA. Apfel
A. Apfel
HSH. Serhan
H. Serhan
PUP. Ulintz
P. Ulintz
SMSofia Merajver
Sofia Merajver

8 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
GSGuan Shi
Guan Shi
HCHao Chen
Hao Chen
PJPu Jia
Pu Jia
LBLi Bao
Li Bao
MCMengmeng Chen
Mengmeng Chen
FFFei Feng
Fei Feng
Objective Through the retrospective study, the efficacy and safety of percutaneous vertebroplasty (PVP) in the treatment of cervical and upper thoracic metastases were evaluated. Through survival analysis, the accuracy of traditional spine metastases scoring system was evaluated, the prognostic factors affecting patients' survival outcomes were explored, and a new survival prediction model was established. Methods We retrospectively selected 85 patients with advanced cervical and upper thoracic metastases who were treated at Beijing Friendship Hospital from October 2012 to February 2018, including 65 patients with PVP surgery and 20 patients with internal medicine. All patients were in advanced stage of the tumor with severe neck and back pain, no spinal cord compression, and the estimated survival time was less than 6 months (Tokuhashi correction score ≤ 8 points or Tomita score ≥ 7 points). We collected basic patient information and survival time, as well as efficacy indicators before treatment and 3 days, 3 months, and 6 months after treatment, including VAS score, analgesic score, neck disability index (NDI), and daily life. State score (Karnofsky performance socre, KPS). Firstly, the differences in the efficacy index before and after PVP surgery, as well as the difference between the surgical and non-surgical treatment effects were compared. Secondly, the accuracy of Tokuhashi correction score, Tomita score and modified Bauer score was evaluated, and the difference in survival time of patients with different treatment methods was compared. Finally, the prognostic factors affecting the survival outcome were screened out and a new survival prediction model was constructed. Results All PVP surgery were successfully completed without serious complications. The cement leakage rates of the cervical and upper thoracic groups were 46.88% (15/32) and 33.87% (21/62), respectively. VAS score, analgesic score, NDI index and KPS score of PVP in cervical spine group were significantly improved compared with preoperative (P<0.05). VAS score, analgesic score, NDI score, and KPS score were also significantly improved in the upper thoracic group after PVP (P<0.001). There was no significant difference in the VAS score (P=0.341), analgesic score (P=0.444), and KPS score (P=0.587) between the cervical spine group and the upper thoracic spine group, but the NDI index of the cervical spine group improved better ( P < 0.001). Compared with the non-surgical group, the surgical group had better improvement in VAS score (P<0.001) and analgesic score (P=0.011), but there was no significant difference in KPS score (P=0.062). The area under the ROC curve for Tomita score was [0.679 (6 months), 0.793 ( 12 months), 0.756 (18 months)] and the predictive power of Tomita score was better than that of Tokuhashi correction score and modified Bauer score. The median survival time was 9 months in both surgical and non-surgical groups, with no significant difference (P=0.183). The median survival time of patients in the traditional medical treatment combined with target therapy group and the traditional medical treatment group were 16 months and 8 months, respectively, and the difference was significant (P<0.001). Tumor type, KPS score, targeted therapy, organ metastasis and bone metastasis were important prognostic factors affecting the survival outcome of patients with advanced cervical and upper thoracic metastases. Through these five factors, a new survival prediction model was established, the area under the ROC curve was [0.869 (6 months), 0.915 (12 months), 0.910 (18 months)], and the predictive ability was better than Tomita scoring system. Conclusion For patients with advanced cervical and upper thoracic metastases with short life expectancy, PVP could effectively relieve neck and back pain symptoms, improve quality of life. The analgesic effect of PVP surgery was better than that of conservative treatment, but there was no significant improvement in survival outcome. Targeted therapy was very important for the survival outcome of such patients.